Abel Hall LLC’s Vaxcyte PCVX Stock Holding History

Abel Hall LLC’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,463	Closed	-$376K	–	1055
2026 Q1	$376K	Buy	+6,463	New	+$351K	0.08%	308

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Abel Hall LLC's PCVX Position: Q2 2026 in Review

Abel Hall LLC sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 6,463 shares — an estimated $376K sold.

Abel Hall LLC first reported a position in PCVX in Q1 2026 and held it in 1 quarter. The position peaked at $376K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Abel Hall LLC reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Abel Hall LLC sold 6,463 Vaxcyte shares in Q2 2026, an estimated $376K.
Abel Hall LLC first reported a position in Vaxcyte in Q1 2026 and held it in 1 quarter.
Abel Hall LLC's Vaxcyte position peaked at $376K in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.